Please login to the form below

Not currently logged in
Email:
Password:

Roche collaborates with German biotech

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Germany

Kinaxo Biotechnologies has entered into a collaboration with Roche Diagnostics in Penzberg, Germany. Under the agreement, Kinaxo's phosphoproteomics technology, PhosphoScout, will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement have not been disclosed.

PhosphoScout is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the unbiased analysis of 15,000 phosphorylation sites in a single experiment.

Dr Klaus Godl, Kinaxo's chief scientific officer, commented: "We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs."

Kinaxo also works with Johnson & Johnson, Bayer and Boehringer Ingelheim.

21st October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics